BioSpace News Archive

Bio NC

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Pharmaceuticals Inc. announced that new data on oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema will be presented at the European Academy of Allergy and Clinical Immunology meeting in Valencia, Spain from May 31 to June 3, 2024.

May 14, 2024
·
5 min read
Drug Development

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced the initiation of a Phase 2 study evaluating the safety and efficacy of navacaprant in people with bipolar depression.

May 14, 2024
·
7 min read
Biotech Beach

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

Zentalis® Pharmaceuticals, Inc. announced that members of the management team will participate in a virtual fireside chat during the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA on May 28, 2024 at 10:30 a.m. ET.

May 14, 2024
·
2 min read
Business

Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update

Mural Oncology plc announced financial results for the first quarter of 2024 and provided a business update.

May 14, 2024
·
12 min read
Drug Development

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA®, a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related events across a diverse population of patients, including patients with preserved ejection fraction.

May 14, 2024
·
10 min read
Business

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals, Inc. reported financial results for the first quarter of 2024 and provided a business update.

May 14, 2024
·
12 min read
Business

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately.

May 14, 2024
·
5 min read
BioMidwest

Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

Axogen, Inc. will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference in Austin, TX, on Wednesday, May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET.

May 14, 2024
·
3 min read
Biotech Beach

Element Biosciences Announces Record Sequencer Installation Growth Ahead of Participation in Investor Conferences

Element Biosciences, Inc., developer of pioneering technologies to empower science, announced record growth in installations of its AVITI™ System ahead of its participation in upcoming investor conferences.

May 14, 2024
·
2 min read
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Alkermes plc announced the presentation of research related to its psychiatry franchise products—LYBALVI® and ARISTADA® —at four scientific conferences this spring.

May 14, 2024
·
20 min read